References
- Abedon ST.: Phage therapy of pulmonary infections. Bacteriophage 5(1), e1020260 (2015) DOI:10.1080/21597081.2015.1020260
- Adesanya O, Oduselu T, Akin-Ajani O, Adewumi OM, Ademowo OG.: An exegesis of bacteriophage therapy: An emerging player in the fight against anti-microbial resistance. AIMS Microbiol. 6(3), 204–230 (2020) DOI:10.3934/microbiol.2020014
- Aslam S, Courtwright AM, Koval C, Lehman SM, Morales S, Furr C-LL, Rosas F, Brownstein MJ, Fackler JR, Sisson BM, et al.: Early clinical experience of bacteriophage therapy in 3 lung transplant recipients. Am J Transplant. 19(9), 2631–2639 (2019) DOI:10.1111/ajt.15503.
- Basak Erol H, Kaskatepe B, Gocmen D, Ziraman FG.: The treatment of Enterococcus faecalis related root canal biofilms with phage therapy. Microb Pathog. 197, 107081 (2024) DOI:10.1016/j.micpath.2024.107081
- Birt MC, Anderson DW, Toby EB, Wang J.: Osteomyelitis: Recent advances in pathophysiology and therapeutic strategies. J Orthop. 14(1), 45–52 (2016) DOI:10.1016/j.jor.2016.10.004
- Cao X, Yu T, Sun Z, Chen M, Xie W, Pang Q, Deng H.: Engineered phages in anti-infection and anti-tumor fields: A review. Microb Pathog. 198, 107052 (2025) DOI:10.1016/j.micpath.2024.107052
- Carmody LA, Gill JJ, Summer EJ, Sajjan US, Gonzalez CF, Young RF, LiPuma JJ.: Efficacy of bacteriophage therapy in a model of Burkholderia cenocepacia pulmonary infection. J Infect Dis. 201(2), 264 (2010) DOI:10.1086/649227
- Chan BK, Abedon, Stephen T, and Loc-Carrillo C. 2013. Phage Cocktails and the Future of Phage Therapy. Future Microbiol. 8(6):769–783. doi:10.2217/fmb.13.47
- Chanishvili N. 2012. Chapter 1-Phage Therapy—History from Twort and d’Herelle Through Soviet Experience to Current Approaches. In: Łobocka M, Szybalski W, editors. Advances in Virus Research. Vol. 83. Academic Press. (Bacteriophages, Part B). p. 3–40 [accessed 2025 Feb 21] https://www.sciencedirect. com/science/article/pii/B9780123944382000013
- Chung KM, Nang SC, Tang SS.: The Safety of Bacteriophages in Treatment of Diseases Caused by Multidrug-Resistant Bacteria. Pharmaceuticals. 16(10), 1347 (2023) DOI:10.3390/ph16101347
- Clarke AL, De Soir S, Jones JD.: The Safety and Efficacy of Phage Therapy for Bone and Joint Infections: A Systematic Review. Antibiotics 9(11), 795 (2020) DOI:10.3390/antibiotics9110795
- Cobb LH, McCabe EM, Priddy LB.: Therapeutics and delivery vehicles for local treatment of osteomyelitis. J Orthop Res Off Publ Orthop Res Soc. 38(10), 2091–2103 (2020) DOI:10.1002/jor.24689
- Crutchfield ED, Stout BF.: Treatment of staphylococcic infections of the skin by the bacteriophage. Arch Dermatol Syphilol. 22(6), 1010–1021 (1930) DOI:10.1001/archderm.1930.01440180056005
- Cunha BA.: Antibiotic side effects. Med Clin North Am. 85(1), 149–185 (2001) DOI:10.1016/S0025-7125(05)70309-6
- Dąbrowska K.: Phage therapy: What factors shape phage pharmacokinetics and bioavailability? Systematic and critical review. Med Res Rev. 39(5), 2000–2025 (2019) DOI:10.1002/med.21572
- Diallo K, Dublanchet A.: Benefits of Combined Phage–Antibiotic Therapy for the Control of Antibiotic-Resistant Bacteria: A Literature Review. Antibiotics 11(7), 839 (2022) DOI:10.3390/antibiotics11070839.
- Doub JB, Ng VY, Johnson AJ, Slomka M, Fackler J, Horne B, Brownstein MJ, Henry M, Malagon F, Biswas B.: Salvage Bacteriophage Therapy for a Chronic MRSA Prosthetic Joint Infection. Antibiotics 9(5), 241 (2020) DOI:10.3390/antibiotics9050241
- Duplessis C, Biswas B, Hanisch B, Perkins M, Henry M, Quinones J, Wolfe D, Estrella L, Hamilton T.: Refractory Pseudomonas Bacteremia in a 2-Year-Old Sterilized by Bacteriophage Therapy. J Pediatr Infect Dis Soc. 7(3), 253–256 (2018) DOI:10.1093/jpids/pix056
- Easwaran M, Abdelrahman F, Madasamy S, Venkidasamy B.: Phage-delivered melittin for oral squamous cell Carcinoma: A potential therapeutic agent. Int Immunopharmacol. 134, 112163 (2024) DOI:10.1016/j.intimp.2024.112163
- Eskenazi A, Lood C, Wubbolts J, Hites M, Balarjishvili N, Leshkasheli L, Askilashvili L, Kvachadze L, van Noort V, Wagemans J, et al.: Combination of pre-adapted bacteriophage therapy and antibiotics for treatment of fracture-related infection due to pandrug-resistant Klebsiella pneumoniae. Nat Commun. 13(1), 302 (2022) DOI:10.1038/s41467-021-27656-z
- Ferry T, Kolenda C, Laurent F, Leboucher G, Merabischvilli M, Djebara S, Gustave C-A, Perpoint T, Barrey C, Pirnay J-P, et al.: Personalized bacteriophage therapy to treat pandrug-resistant spinal Pseudomonas aeruginosa infection. Nat Commun. 13(1), 4239 (2022) DOI:10.1038/s41467-022-31837-9
- Frieri M, Kumar K, Boutin A.: Antibiotic resistance. J Infect Public Health. 10(4), 369–378 (2017) DOI:10.1016/j. jiph.2016.08.007
- Fruciano DE, Bourne S.: Phage as an Antimicrobial Agent: D’herelle’s Heretical Theories and Their Role in the Decline of Phage Prophylaxis in the West. Can J Infect Dis Med Microbiol. 18(1), 976850 (2007) DOI:10.1155/2007/976850
- Gordillo Altamirano FL, Barr JJ.: Phage Therapy in the Postantibiotic Era. Clin Microbiol Rev. 32(2), e00066-18 (2019) DOI:10.1128/cmr.00066-18
- Górski A, Jończyk-Matysiak E, Łusiak-Szelachowska M, Międzybrodzki R, Weber-Dąbrowska B, Borysowski J.: The Potential of Phage Therapy in Sepsis. Front Immunol. 8, 1783 (2017) DOI:10.3389/fimmu.2017.01783
- Guerrero-Bustamante CA, Dedrick RM, Garlena RA, Russell DA, Hatfull GF.: Toward a Phage Cocktail for Tuberculosis: Susceptibility and Tuberculocidal Action of Mycobacteriophages against Diverse Mycobacterium tuberculosis Strains. mBio. 12(3), e00973-21 (2021) DOI:10.1128/mbio.00973-21
- Guo X, Wang X, Shi J, Ren J, Zeng J, Li J, Li Y.: A review and new perspective on oral bacteriophages: manifestations in the ecology of oral diseases. J Oral Microbiol. 16(1), 2344272 (2024) DOI:10.1080/20002297.2024.2344272
- Hampton HG, Watson BNJ, Fineran PC.: The arms race between bacteria and their phage foes. Nature. 577(7790), 327– 336 (2020) DOI:10.1038/s41586-019-1894-8
- Hanlon GW, Denyer SP, Olliff CJ, Ibrahim LJ.: Reduction in Exopolysaccharide Viscosity as an Aid to Bacteriophage Penetration through Pseudomonas aeruginosa Biofilms. Appl Environ Microbiol. 67(6), 2746–2753 (2001) DOI:10.1128/AEM.67.6.2746-2753.2001
- Hashimoto K, Yoshinari M, Matsuzaka K, Shiba K, Inoue T.: Identification of peptide motif that binds to the surface of zirconia. Dent Mater J. 30(6), 935–940 (2011) DOI:10.4012/dmj.2011-161
- Ho K.: Bacteriophage Therapy for Bacterial Infections: Rekindling a Memory from the Pre-Antibiotics Era. Perspect Biol Med. 44(1), 1–16 (2001)
- Ho Y-H, Tseng C-C, Wang L-S, Chen Y-T, Ho G-J, Lin T-Y, Wang L-Y, Chen L-K.: Application of Bacteriophage-containing Aerosol against Nosocomial Transmission of Carbapenem-Resistant Acinetobacter baumannii in an Intensive Care Unit. PLOS ONE. 11(12), e0168380 (2016) DOI:10.1371/journal.pone.0168380
- Hofstee MI, Muthukrishnan G, Atkins GJ, Riool M, Thompson K, Morgenstern M, Stoddart MJ, Richards RG, Zaat SAJ, Moriarty TF.: Current Concepts of Osteomyelitis: From Pathologic Mechanisms to Advanced Research Methods. Am J Pathol. 190(6), 1151–1163 (020) DOI:10.1016/j.ajpath.2020.02.007
- Howard-Jones AR, Iredell JR, Khatami A.: Phage therapy in pediatrics: the way forward for difficult-to-treat infections? Expert Rev Anti Infect Ther. 20(4), 487–491 (2020) DOI:10.1080/14787210.2022.1990755
- Ibrahim N, Apandi NIM, Shuhardi SA, Ramli R.: Actinomyces sp. Presence in the Bone Specimens of Patients with Osteonecrosis of the Jaw: The Histopathological Analysis and Clinical Implication. Antibiotics 11(8), 1067 (2022) DOI:10.3390/antibiotics11081067
- Inchley CJ.: The activity of mouse Kupffer cells following intravenous injection of T4 bacteriophage. Clin Exp Immunol. 5(2), 173–187 (1969)
- Jandl B, Dighe S, Baumgartner M, Makristathis A, Gasche C, Muttenthaler M.: Gastrointestinal Biofilms: Endoscopic Detection, Disease Relevance, and Therapeutic Strategies. Gastroenterology 167(6), 1098-1112.e5 (2024) DOI:10.1053/j.gastro.2024.04.032
- Jault P, Leclerc T, Jennes S, Pirnay JP, Que Y-A, Resch G, Rousseau AF, Ravat F, Carsin H, Le Floch R, et al.: Efficacy and tolerability of a cocktail of bacteriophages to treat burn wounds infected by Pseudomonas aeruginosa (PhagoBurn): a randomised, controlled, double-blind phase 1/2 trial. Lancet Infect Dis. 19(1), 35–45 (2019) DOI:10.1016/S1473-3099(18)30482-1
- Khalifa L, Shlezinger M, Beyth S, Houri-Haddad Y, Coppenhagen-Glazer S, Beyth N, Hazan R.: Phage therapy against Enterococcus faecalis in dental root canals. J Oral Microbiol. 8, 32157 (2016) DOI:10.3402/jom.v8.32157
- Khalil M, Di Ciaula A, Mahdi L, Jaber N, Di Palo DM, Graziani A, Baffy G, Portincasa P.: Unraveling the Role of the Human Gut Microbiome in Health and Diseases. Microorganisms 12(11), 2333 (2024) DOI:10.3390/microorganisms12112333
- Kim P, Sanchez AM, Penke TJR, Tuson HH, Kime JC, McKee RW, Slone WL, Conley NR, McMillan LJ, Prybol CJ, et al.: Safety, pharmacokinetics, and pharmacodynamics of LBP-EC01, a CRISPR-Cas3-enhanced bacteriophage cocktail, in uncomplicated urinary tract infections due to Escherichia coli (ELIMINATE): the randomised, open-label, first part of a two-part phase 2 trial. Lancet Infect Dis. 24(12), 1319–1332 (2024) DOI:10.1016/S1473-3099(24)00424-9
- Kishor C, Mishra RR, Saraf SK, Kumar M, Srivastav AK, Nath G.: Phage therapy of staphylococcal chronic osteomyelitis in experimental animal model. Indian J Med Res. 143(1), 87–94 (2016) DOI:10.4103/0971-5916.178615
- de Kraker MEA, Stewardson AJ, Harbarth S.: Will 10 Million People Die a Year due to Antimicrobial Resistance by 2050? PLoS Med. 13(11), e1002184 (2016) DOI:10.1371/journal. pmed.1002184
- Kwon JH, Powderly WG.: The post-antibiotic era is here. Science 373(6554), 471–471 (2021) DOI:10.1126/science.abl5997
- Lehti TA, Pajunen MI, Skog MS, Finne J.: Internalization of a polysialic acid-binding Escherichia coli bacteriophage into eukaryotic neuroblastoma cells. Nat Commun. 8(1), 1915 (2017) DOI:10.1038/s41467-017-02057-3
- Li G-J, Jiang D-Y, Zong X, Xu X.: Keratinocyte growth factor phage model peptides can promote human oral mucosal epithelial cell proliferation. Oral Surg Oral Med Oral Pathol Oral Radiol. 116(2), e92–e97 (2013) DOI:10.1016/j.oooo.2011.12.014
- Li X, He Y, Wang Z, Wei J, Hu T, Si J, Tao G, Zhang L, Xie L, Abdalla AE, et al.: A combination therapy of Phages and Antibiotics: Two is better than one. Int J Biol Sci. 17(13), 3573–3582 (2021) DOI:10.7150/ijbs.60551
- Lin DM, Koskella B, Lin HC.: Phage therapy: An alternative to antibiotics in the age of multi-drug resistance. World J gastrointest Pharmacol Ther. 8(3), 162–173 (2017) DOI:10.4292/wjgpt.v8.i3.162
- MacNEAL WJ, Filak L, Blevins A.: Conjoined action of penicillin and bacteriophages. J Lab Clin Med. 31, 974–981 (1946)
- Malik DJ, Sokolov IJ, Vinner GK, Mancuso F, Cinquerrui S, Vladisavljevic GT, Clokie MRJ, Garton NJ, Stapley AGF, Kirpichnikova A.: Formulation, stabilisation and encapsulation of bacteriophage for phage therapy. Adv Colloid Interface Sci. 249, 100–133 (2017) DOI:10.1016/j.cis.2017.05.014
- Mancuso G, Midiri A, Gerace E, Biondo C.: Bacterial Antibiotic Resistance: The Most Critical Pathogens. Pathogens 10(10), 1310 (2021) DOI:10.3390/pathogens10101310
- Marongiu L, Burkard M, Lauer UM, Hoelzle LE, Venturelli S.: Reassessment of Historical Clinical Trials Supports the Effectiveness of Phage Therapy. Clin Microbiol Rev. 35(4), e0006222 (2022) DOI:10.1128/cmr.00062-22
- Meng Xiangpeng, Shi Y, Ji W, Meng Xueling, Zhang J, Wang H, Lu C, Sun J, Yan Y.: Application of a Bacteriophage Lysin To Disrupt Biofilms Formed by the Animal Pathogen Streptococcus suis. Appl Environ Microbiol. 77(23), 8272–8279 (2011) DOI:10.1128/AEM.05151-11
- Miethke M, Pieroni M, Weber T, Brönstrup M, Hammann P, Halby L, Arimondo PB, Glaser P, Aigle B, Bode HB, et al.: Towards the sustainable discovery and development of new antibiotics. Nat Rev Chem. 5(10), 726–749 (2021) DOI:10.1038/s41570-021-00313-1
- Nale JY, Spencer J, Hargreaves KR, Buckley AM, Trzepiński P, Douce GR, Clokie MRJ.: Bacteriophage Combinations Significantly Reduce Clostridium difficile Growth In Vitro and Proliferation In Vivo. Antimicrob Agents Chemother. 60(2), 968–981 (2016) DOI:10.1128/aac.01774-15
- Naureen Z, Dautaj A, Anpilogov K, Camilleri G, Dhuli K, Tanzi B, Maltese PE, Cristofoli F, Antoni LD, Beccari T, et al.: Bacteriophages presence in nature and their role in the natural selection of bacterial populations. Acta Biomed Atenei Parm. 91(13-S), e2020024–e2020024 (2020) DOI:10.23750/abm. v91i13-S.10819
- Nir-Paz R, Gelman D, Khouri A, Sisson BM, Fackler J, Alkalay-Oren S, Khalifa L, Rimon A, Yerushalmy O, Bader R, et al.: Successful Treatment of Antibiotic-resistant, Poly-microbial Bone Infection With Bacteriophages and Antibiotics Combination. Clin Infect Dis. 69(11), 2015–2018 (2019) DOI:10.1093/cid/ciz222
- Nobrega FL, Vlot M, de Jonge PA, Dreesens LL, Beaumont HJE, Lavigne R, Dutilh BE, Brouns SJJ.: Targeting mechanisms of tailed bacteriophages. Nat Rev Microbiol. 16(12), 760–773 (2018) DOI:10.1038/s41579-018-0070-8
- Obuobi S, Škalko-Basnet N.: Understanding vaginal biofilms: The first step in harnessing antimicrobial nanomedicine. J Controlled Release. 376, 1190–1208 (2024) DOI:10.1016/j.jconrel.2024.10.064
- Onsea J, Soentjens P, Djebara S, Merabishvili M, Depypere M, Spriet I, De Munter P, Debaveye Y, Nijs S, Vanderschot P, et al.: Bacteriophage Application for Difficult-to-treat Musculoskeletal Infections: Development of a Standardized Multidisciplinary Treatment Protocol. Viruses 11(10), 891 (2019) DOI:10.3390/v11100891
- Palma M, Qi B.: Advancing Phage Therapy: A Comprehensive Review of the Safety, Efficacy, and Future Prospects for the Targeted Treatment of Bacterial Infections. Infect Dis Rep. 16(6), 1127–1181 (2024) DOI:10.3390/idr16060092
- Pazhouhnia S, Bouzari M, Arbabzadeh-Zavareh F.: Isolation, characterization and complete genome analysis of a novel bacteriophage vB_EfaS-SRH2 against Enterococcus faecalis isolated from periodontitis patients. Sci Rep. 12(1), 13268 (2022) DOI:10.1038/s41598-022-16939-0
- Peng Jiaze, Guo C, Yang C, Zhang L, Yang F, Huang X, Yu Y, Zhang T, Peng Jiachen.: Phage therapy for bone and joint infections: A comprehensive exploration of challenges, dynamics, and therapeutic prospects. J Glob Antimicrob Resist. 39, 12–21 (2024) DOI:10.1016/j.jgar.2024.07.007
- Phage Targeting Streptococcus mutans In Vitro and In Vivo as a Caries-Preventive Modality. [accessed 2025 May 25]. https://www.mdpi.com/2079-6382/10/8/1015
- Pirnay J-P, Djebara S, Steurs G, Griselain J, Cochez C, De Soir S, Glonti T, Spiessens A, Vanden Berghe E, Green S, et al.: Personalized bacteriophage therapy outcomes for 100 consecutive cases: a multicentre, multinational, retrospective observational study. Nat Microbiol. 9(6), 1434–1453 (2024) DOI:10.1038/s41564-024-01705-x
- Qadir MI, Mobeen T, Masood A.: Phage therapy: progress in pharmacokinetics. Braz J Pharm Sci. 54, e17093 (2018) DOI: https://doi.org/10.1590/s2175-97902018000117093
- Rath S, Bal SCB, Dubey D.: Oral Biofilm: Development Mechanism, Multidrug Resistance, and Their Effective Management with Novel Techniques. Rambam Maimonides Med J. 12(1), e0004 (2021) DOI:10.5041/RMMJ.10428
- Rotman SG, Sumrall E, Ziadlou R, Grijpma DW, Richards RG, Eglin D, Moriarty TF.: Local Bacteriophage Delivery for Treatment and Prevention of Bacterial Infections. [accessed 2025 Jun 9] Front Microbiol. 11 (2020) DOI:10.3389/fmicb.2020.538060 https://www.frontiersin.org/journals/microbiology/articles/10.3389/fmicb.2020.538060/full.
- Safari F, Sharifi, Mehrdad, Farajnia, Safar, Akbari, Bahman, Karimi Baba Ahmadi, Mohammad, Negahdaripour, Manica, and Ghasemi Y.: The interaction of phages and bacteria: the co-evolutionary arms race. Crit Rev Biotechnol. 40(2), 119–137 (2020) DOI:10.1080/07388551.2019.1674774
- Săndulescu M, Sîrbu VD, Popovici IA.: Bacterial species associated with peri-implant disease – a literature review. Germs. 13(4), 352–361 (2023) DOI:10.18683/germs.2023.1405
- Sawa T, Moriyama K, Kinoshita M.: Current status of bacteriophage therapy for severe bacterial infections. J Intensive Care. 12(1), 44 (2024) DOI:10.1186/s40560-024-00759-7
- Simner PJ, Cherian J, Suh GA, Bergman Y, Beisken S, Fackler J, Lee M, Hopkins RJ, Tamma PD.: Combination of phage therapy and cefiderocol to successfully treat Pseudomonas aeruginosa cranial osteomyelitis. JAC-Antimicrob Resist. 4(3), dlac046 (2022) DOI:10.1093/jacamr/dlac046
- Singla S, Harjai K, Katare OP, Chhibber S.: Bacteriophage-Loaded Nanostructured Lipid Carrier: Improved Pharmacokinetics Mediates Effective Resolution of Klebsiella pneumoniae–Induced Lobar Pneumonia. J Infect Dis. 212(2), 325–334 (2015) DOI:10.1093/infdis/jiv029
- Socransky SS, Haffajee AD, Cugini MA, Smith C, Kent RL.: Microbial complexes in subgingival plaque. J Clin Periodontol. 25(2), 134–144 (1998) DOI:10.1111/j.1600-051x.1998. tb02419.x
- Speck P, Smithyman A.: Safety and efficacy of phage therapy via the intravenous route. FEMS Microbiol Lett. 363(3), fnv242 (2016) DOI:10.1093/femsle/fnv242
- Štrancar V, Marušić M, Tušar J, Praček N, Kolenc M, Šuster K, Horvat S, Janež N, Peterka M.: Isolation and in vitro characterization of novel S. epidermidis phages for therapeutic applications. Front Cell Infect Microbiol. 13, 1169135 (2023) DOI:10.3389/fcimb.2023.1169135
- Suh GA, Ferry T, Abdel MP.: Phage Therapy as a Novel Therapeutic for the Treatment of Bone and Joint Infections. Clin Infect Dis. 77(Supplement_5), S407–S415 (2023) DOI:10.1093/cid/ciad533
- Suh GA, Lodise TP, Tamma PD, Knisely JM, Alexander J, Aslam S, Barton KD, Bizzell E, Totten KMC, Campbell JL, et al.: Considerations for the Use of Phage Therapy in Clinical Practice. Antimicrob Agents Chemother. 66(3), e02071-21 (2022) DOI:10.1128/aac.02071-21
- SUMMERS WC.: Cholera and Plague in India: The Bacteriophage Inquiry of 1927–1936. J Hist Med Allied Sci. 48(3), 275– 301 (1993) DOI:10.1093/jhmas/48.3.275
- Summers WC.: Bacteriophage Therapy. Annu Rev Microbiol. 55, 437–451 (2001) DOI:10.1146/annurev.micro.55.1.437
- Summers WC.: The strange history of phage therapy. Bacteriophage 2(2), 130–133 (2012) DOI:10.4161/bact.20757
- Szafrański SP, Winkel A, Stiesch M.: The use of bacteriophages to biocontrol oral biofilms. J Biotechnol. 250, 29–44 (2017) DOI:10.1016/j.jbiotec.2017.01.002
- de Tejada GM, Heinbockel L, Ferrer-Espada R, Heine H, Alexander C, Bárcena-Varela S, Goldmann T, Correa W, Wiesmüller K-H, Gisch N, et al.: Lipoproteins/peptides are sepsis-inducing toxins from bacteria that can be neutralized by synthetic anti-endotoxin peptides. Sci Rep. 5(1), 14292 (2015) DOI:10.1038/srep14292
- Teklemariam AD, Al-Hindi RR, Qadri I, Alharbi MG, Ramadan WS, Ayubu J, Al-Hejin AM, Hakim Raghad F., Hakim FF, Hakim Rahad F., et al.: The Battle between Bacteria and Bacteriophages: A Conundrum to Their Immune System. Antibiotics 12(2), 381 (2023) DOI:10.3390/antibiotics12020381
- Tinoco JM, Liss N, Zhang H, Nissan R, Gordon W, Tinoco E, Sassone L, Stevens R.: Antibacterial effect of genetically-engineered bacteriophage ϕEf11/ϕFL1C(Δ36)PnisA on dentin infected with antibiotic-resistant Enterococcus faecalis. Arch Oral Biol. 82, 166–170 (2017) DOI:10.1016/j.archoralbio.2017.06.005
- Tseng C-C, Chen L-K, Chu H-T, Chen Y-T, Jiang H-L, Yang H-H, Chang C-C, Debangana S, Ponge L-M, Li M-X, et al.: Prophylactic phage aerosols for nosocomial infection control in an extracorporeal membrane oxygenation unit: A 4-year prospective study of temporospatially designed phage cocktails. Int J Antimicrob Agents. 65(2), 107413 (2025) DOI:10.1016/j.ijantimicag.2024.107413
- Turner D, Shkoporov AN, Lood C, Millard AD, Dutilh BE, Alfenas-Zerbini P, van Zyl LJ, Aziz RK, Oksanen HM, Poranen MM, et al.: Abolishment of morphology-based taxa and change to binomial species names: 2022 taxonomy update of the ICTV bacterial viruses subcommittee. Arch Virol. 168(2), 74 (2023) DOI:10.1007/s00705-022-05694-2
- Uyttebroek S, Chen B, Onsea J, Ruythooren F, Debaveye Y, Devolder D, Spriet I, Depypere M, Wagemans J, Lavigne R, et al.: Safety and efficacy of phage therapy in difficult-to-treat infections: a systematic review. Lancet Infect Dis. 22(8), e208– e220 (2022) DOI:10.1016/S1473-3099(21)00612-5
- Ventola CL.: The antibiotic resistance crisis: part 1: causes and threats. Pharm Ther. 40(4), 277–283 (2015)
- Vila MMDC, Balcão LMN, Balcão VM.: Phage Delivery Strategies for Biocontrolling Human, Animal, and Plant Bacterial Infections: State of the Art. Pharmaceutics 16(3), 374 (2024) DOI:10.3390/pharmaceutics16030374
- Wittebole X, De Roock S, Opal SM.: A historical overview of bacteriophage therapy as an alternative to antibiotics for the treatment of bacterial pathogens. Virulence 5(1), 226–235 (2014) DOI :10.4161/viru.25991
- Wolfoviz-Zilberman A, Kraitman R, Hazan R, Friedman M, Houri-Haddad Y, Beyth N.: Phage Targeting Streptococcus mutans In Vitro and In Vivo as a Caries-Preventive Modality. Antibiotics 10(8), 1015 (2021) DOI:10.3390/antibiotics10081015
- Wu C, Fujiki J, Mathieu J, Schwarz C, Cornell C, Alvarez PJJ.: Phage-based biocontrol of Porphyromonas gingivalis through indirect targeting. Appl Environ Microbiol. 90(10), e00951-24 (2024) DOI:10.1128/aem.00951-24
- Xu Z, Ding Z, Zhang Y, Liu X, Wang Q, Shao S, Liu Q.: Shelf-life prediction and storage stability of Aeromonas bacteriophage vB_AsM_ZHF. Virus Res. 323, 198997 (2023) DOI:10.1016/j. virusres.2022.198997
- Yang Q, Le S, Zhu T, Wu N.: Regulations of phage therapy across the world. Front Microbiol. 14, 1250848 (2023) DOI:10.3389/fmicb.2023.1250848
- Yuan Y, Qu K, Tan D, Li X, Wang L, Cong C, Xiu Z, Xu Y.: Isolation and characterization of a bacteriophage and its potential to disrupt multi-drug resistant Pseudomonas aeruginosa biofilms. Microb Pathog. 128, 329–336 (2019) DOI:10.1016/j. micpath.2019.01.032
- Zhai L, Yadav R, Kunda NK, Anderson D, Bruckner E, Miller EK, Basu R, Muttil P, Tumban E.: Oral immunization with bacteriophage MS2-L2 VLPs protects against oral and genital infection with multiple HPV types associated with head & neck cancers and cervical cancer. Antiviral Res. 166, 56–65 (2019) DOI:10.1016/j.antiviral.2019.03.012
- Zhang Y, Shan T-L, Li F, Yu T, Chen X, Deng X-T, Delwart E, Feng X-P.: A novel phage from periodontal pockets associated with chronic periodontitis. Virus Genes 55(3), 381–393 (2019) DOI:10.1007/s11262-019-01658-y
- Zhu M, Hao C, Zou T, Jiang S, Wu B.: Phage therapy as an alternative strategy for oral bacterial infections: a systematic review. BMC Oral Health 25(1), 44 (2025) doi:10.1186/s12903-024-05399-9